Aortic stenosis
Mechanistic, epidemiologic and genetic evidence converges on Lp(a) as a causal driver of both atherosclerosis and aortic stenosis, a review of emerging therapies (J Clin Med 2022)
Original title: Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies
This review compiles mechanistic, epidemiological and genetic evidence supporting Lp(a) as a causal risk factor for both atherosclerotic cardiovascular disease and aortic stenosis/calcific aortic valve disease. The authors note that treatment options for elevated Lp(a) remain limited, but several targeted therapies are progressing through clinical development. The review details the evidentiary basis for Lp(a) causality and discusses current approaches to managing Lp(a)-associated cardiovascular risk.
Original abstract
Lipoprotein(a) (Lp(a)) is an established risk factor for multiple cardiovascular diseases. Several lines of evidence including mechanistic, epidemiologic, and genetic studies support the role of Lp(a) as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis/calcific aortic valve disease (AS/CAVD). Limited therapies currently exist for the management of risk associated with elevated Lp(a), but several targeted therapies are currently in various stages of clinical development. In this review, we detail evidence supporting Lp(a) as a causal risk factor for ASCVD and AS/CAVD, and discuss approaches to managing Lp(a)-associated risk.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.